Claims for Patent: 4,886,808

Summary for Patent: 4,886,808

Title:	Indazolyl carboxylic acid amides useful for treating migraine clusters headache, trigeminal neuralgia or emesis
Abstract:	Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein X is CO and Y is NH; Z is NR.sub.3 wherein R.sub.3 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 alkenyl-methyl, phenyl or phenyl C.sub.1-4 alkyl either of which phenyl moieties may be substituted by one or two of halogen, CF.sub.3, C.sub.1-6 alkoxy or C.sub.1-6 alkyl; and R.sub.a is not present; or Z is N and R.sub.a is as defined for R.sub.3 above; R.sub.b is present when X-Y-R.sub.2 is attached at the phenyl ring and is selected from hydrogen, halogen, CF.sub.3, hydroxy, C.sub.1-6 alkoxy or C.sub.1-6 alkyl; R.sub.1 is hydrogen, halogen, CF.sub.3, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonylamino, N(C.sub.1-6 alkylsulphonyl)-N-C.sub.1-4 alkylamino, C.sub.1-6 alkylsulphinyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C.sub.1-4 alkylamino optionally N-substituted by one or two groups selected from C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups or optionally N-disubstituted by C.sub.4-5 polymethylene; R.sub.2 is a group of formula (a) ##STR2## wherein n is 2 or 3; and R.sub.4 is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alkyl, or a group (CH.sub.2).sub.t R.sub.6 where t is 1 or 2 and R.sub.6 is thienyl, pyrrolyl or furyl optionally substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents having 5-HT antagonist activity and/or gastric motility enhancing activity.
Inventor(s):	King; Francis D. (Bishop's Stortford, GB2)
Assignee:	Beecham Group p.l.c. (Brentford, GB2)
Application Number:	07/171,141
Patent Claims:	1. A compound of formula (I), or a pharmaceutically acceptable salt thereof: ##STR22## wherein X is CO and Y is NH; Z is NR.sub.3 wherein R.sub.3 is hydrogen, C.sub.1-6 alkyl, C.sub.3-7 alkenyl-methyl, phenyl or phenyl C.sub.1-4 alkyl either of which phenyl moieties may be substituted by one or two of halogen, CF.sub.3, C.sub.1-6 alkoxy or C.sub.1-6 alkyl; R.sub.b is present when X-Y-R.sub.2 is attached at the phenyl ring and is selected from hydrogen, halogen, CF.sub.3, hydroxy, C.sub.1-6 alkoxy or C.sub.1-6 alkyl; R.sub.1 is hydrogen, halogen, CF.sub.3, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkylthio, C.sub.1-7 acyl, C.sub.1-7 acylamino, C.sub.1-6 alkylsulphonylamino, N-(C.sub.1-6 alkylsulphonyl)-N-C.sub.1-4 alkylamino, C.sub.1-6 alkylsulphinyl, hydroxy, nitro or amino, aminocarbonyl, aminosulphonyl, aminosulphonylamino or N-(aminosulphonyl)-C.sub.1-4 alkylamino optionally N-substituted by one or two groups selected from C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl C.sub.1-4 alkyl, phenyl or phenyl C.sub.1-4 alkyl groups or optionally N-disubstituted by C.sub.4-5 polymethylene; R.sub.2 is a group of formula (a), ##STR23## wherein n is 2 or 3; and R.sub.4 is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alkyl, or a group (CH.sub.2).sub.t R.sub.6 where t is 1 or 2 and R.sub.6 is thienyl, pyrrolyl or furyl optionally substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C.sub.1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C.sub.1-4 alkyl optionally substituted by hydroxy, C.sub.1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolysable acyloxy. 2. A compound according to claim 1 wherein n is 3. 3. A compound according to claim 1 wherein R.sub.3 is hydrogen or methyl. 4. A compound according to claim 1 wherein the X-Y-R.sub.2 side chain is attached at position 3, as depicted in formula (I) in claim 1. 5. A compound according to claim 1 wherein R.sub.1 is hydrogen or 5-halo. 6. A compound according to claim 1 wherein R.sub.4 is C.sub.1-7 alkyl. 7. A compound according to claim 4 wherein R.sub.4 is methyl. 8. A compound selected from the group consisting of: N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-indazole-3carboxamide, N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-5-fluoroindazole-3-carboxamid e, N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-5-chloroindazole-3-carboxamid e, N-(endo-9-methyl-9-azabicyclo[3.3.2]non-3-yl)-1-methylindazole-3-carboxamid e, N-(endo-9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-ethylindazole-3-carboxamide , and pharmaceutically acceptable salts of any of the foregoing. 9. A compound according to claim 1 wherein Y-R.sub.2 is in the endo configuration. 10. N-(Endo-9-m ethyl-9-azabicyclo[3.3.1]non-3-yl)-1-methylindazole-3-carboxamide monohydrochloride. 11. A pharmaceutical composition for the treatment of migraine or cluster headache, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 12. A pharmaceutical composition for the treatment of trigeminal neuralgia, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 13. A pharmaceutical composition for the treatment of emesis, comprising an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 14. A method of treatment or prophylaxis of migraine or cluster headache in mammals, which comprises the administration to the mammal of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 15. A method of treatment or prophylaxis of trigeminal neuralgia in mammals, which comprises the administration to the mammal of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 16. A method of treatment or prophylaxis of emesis in mammals, which comprises the administration to the mammal of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 17. A method of treatment of anxiety in mammals, which comprises the administration to the mammal of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 18. A method of treatment of psychosis in mammals, which comprises the administration to the mammal of an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof. 19. A pharmaceutical composition for the treatment of anxiety, comprising an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier. 20. A pharmaceutical composition for the treatment of psychosis, comprising an effective amount of a compond according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.